IL2 and cancer: • CD39+ and CD73+ EVs.• Spread of EVs to TDLN and metastatic sites.• IL-2 is available to both CD8 and Treg for their expansion.• MTAP loss variant cancers bypass direct A2AR antagonist blocking.